Pay in 4 interest-free payments of $6.49 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Stopping or ending it
Individuals seeking comprehensive cognitive and mental performance support
RGN-352 was shown to be safe and well-tolerated with no serious drug-related adverse events reported (PMID: 20536472) Phase 2 AMI trial (incomplete): RegeneRx designed a Phase 2 proof-of-concept trial (NCT01311518) to evaluate RGN-352 in approximately 75 patients with acute ST-segment elevation myocardial infarction (heart attack)
Science 360 , 751758 (2018)
US$ 27.44
US$ 29.27
US$ 27.32
US$ 25.09
